Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety with an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Trial Identifier: VAM00001
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: November 2022
Primary Completion Date: February 2023
Study Completion Date: February 2024
Condition: Influenza Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
UNITED STATES, Arizona Mesa, Arizona, UNITED STATES, 85206
UNITED STATES, Florida Hallandale Beach, Florida, UNITED STATES, 33009
UNITED STATES, Florida Hollywood, Florida, UNITED STATES, 33024
UNITED STATES, Florida Miami, Florida, UNITED STATES, 33173
UNITED STATES, Florida St. Augustine, Florida, UNITED STATES, 32086
UNITED STATES, Georgia Atlanta, Georgia, UNITED STATES, 30331
UNITED STATES, Indiana Valparaiso, Indiana, UNITED STATES, 46383
UNITED STATES, Louisiana Metairie, Louisiana, UNITED STATES, 70006
UNITED STATES, North Carolina Raleigh, North Carolina, UNITED STATES, 27612
UNITED STATES, Pennsylvania Pittsburgh, Pennsylvania, UNITED STATES, 15243
UNITED STATES, Pennsylvania Pittsburgh, Pennsylvania, UNITED STATES, 15236
UNITED STATES, South Carolina Anderson, South Carolina, UNITED STATES, 29621
UNITED STATES, Tennessee Chattanooga, Tennessee, UNITED STATES, 37421
UNITED STATES, Texas Austin, Texas, UNITED STATES, 78759
UNITED STATES, Utah Salt Lake City, Utah, UNITED STATES, 84107
UNITED STATES, Utah SALT LAKE CITY, Utah, UNITED STATES, 84121